Emergent BioSolutions securities fraud investigation

Levi & Korsinsky, LLP has commenced an investigation into Emergent BioSolutions Inc. (NYSE: EBS) concerning potential violations of federal securities laws. The investigation focuses on whether Emergent adequately disclosed the deterioration in its Naloxone franchise, including competitive and pricing pressures. On February 26, 2026, Emergent issued FY2026 revenue guidance of $720-$760 million and adjusted EBITDA guidance of $135-$155 million, with management attributing softer Naloxone demand to transient factors and stating that pricing had stabilized. On April 30, 2026, the company reaffirmed its revenue guidance and raised adjusted EBITDA guidance to $155-$175 million. However, on August 5, 2026, Emergent reduced its FY2026 revenue guidance to $645-$675 million and adjusted EBITDA guidance to $130-$150 million, a $75 million reduction at the midpoint. The company also recorded a $191.3 million non-cash impairment on its Naloxone franchise due to increased competition and pricing pressure. The investigation concerns whether Emergent's prior statements were materially misleading. Investors who suffered losses are encouraged to contact Levi & Korsinsky.